Revelation Biosciences (NASDAQ:REVB) Posts Earnings Results, Beats Estimates By $0.01 EPS

Revelation Biosciences (NASDAQ:REVB) released its quarterly earnings results on Friday. The company reported ($0.87) EPS for the quarter, topping the consensus estimate of ($0.88) by $0.01, FiscalAI reports.

Revelation Biosciences Price Performance

Shares of NASDAQ REVB opened at $1.14 on Friday. The company has a market cap of $4.46 million, a P/E ratio of -0.09 and a beta of -0.15. Revelation Biosciences has a 1 year low of $0.88 and a 1 year high of $11.72. The firm has a 50-day simple moving average of $1.04 and a two-hundred day simple moving average of $1.27.

Wall Street Analyst Weigh In

Separately, Weiss Ratings downgraded Revelation Biosciences from a “sell (e+)” rating to a “sell (e)” rating in a research report on Tuesday, July 28th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the company has an average rating of “Sell”.

Institutional Investors Weigh In On Revelation Biosciences

An institutional investor recently raised its stake in Revelation Biosciences stock. Armistice Capital LLC raised its holdings in Revelation Biosciences, Inc. (NASDAQ:REVB) by 442.8% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 434,272 shares of the company’s stock after acquiring an additional 354,272 shares during the quarter. Armistice Capital LLC owned approximately 6.29% of Revelation Biosciences worth $347,000 as of its most recent filing with the Securities & Exchange Commission. 12.80% of the stock is currently owned by institutional investors.

Revelation Biosciences Company Profile

Revelation Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.